<DOC>
	<DOCNO>NCT00685464</DOCNO>
	<brief_summary>The aim study investigate wether intracoronary use bolus Abciximab superior intravenous bolus patient undergo percutaneous coronary intervention .</brief_summary>
	<brief_title>Intravenous Versus Intracoronary Use Abciximab</brief_title>
	<detailed_description>STEMI patient indication adjuvant therapy GPI pPCI , give inform consent , randomize , use seal , opaque envelope , either IC IV bolus ( 0.25 mg/kg body weight ) follow 12-hour IV infusion abciximab ( 0.125 μg/kg body weight per minute ) . IC bolus abciximab deliver via PCI guide catheter directly culprit artery , whereas IV bolus give peripheral vein , filter drug . The drug use centre Reo-Pro® manufacture Eli Lilly , Denmark , involvement , economically scientifically , trial . Inclusion criterion present analysis STEMI ( onset chest pain ≤ 12 hour ST-segment elevation two contiguous lead ≥ 2 mm V1-V3 ≥ 1 mm lead ) , age ≥ 18 year indication adjuvant therapy abciximab ( e.g . bail-out case no-reflow , high thrombus burden , dissection , type B2/C lesion ) operator 's discretion . Exclusion criterion know allergy abciximab , ongoing bleeding , recent stroke , major surgery within 2 month , know bleed disorder , pregnancy . All patient pre-treated oral Aspirin ( 300-500 mg ) Clopidogrel ( 300-600 mg ) 10,000 IU unfractionated heparin give IV single-dose accord national guideline STEMI patient refer pPCI . Patients discharge life-long Aspirin dose 75 mg/day Clopidogrel 12 month dose 75 mg/day . In relation PCI follow data record : infarct localization ECG coronary angiography , number diseased vessel , TIMI flow PCI , lesion type ( A , B , C ) , type number stent implant . Furthermore , follow baseline data register : age , gender , hypertension ( define treat blood pressure lower medication , diagnose hypertension hospital stay , i.e . systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg ) , hypercholesterolemia ( define treat lipid lower medication , in-hospital fasting total cholesterol ≥ 5 mmol/L ( 192 mg/dL ) , LDL ≥ 3 mmol/L ( 116 mg/dL ) ) , smoke status , family history coronary heart disease , diabetes ( define treat anti-diabetic agent , in-hospital fasting plasma glucose ≥ 6.1 mmol/L , non-fasting plasma glucose ≥ 11.1 mmol/L ) , prior coronary vessel disease , height weight . Medication status record admission , discharge , 30-day follow . Left ventricular ejection fraction ( LVEF ) assess hospital stay echocardiography use 16 standard segment model ( 28 ) . Primary end-points define death target vessel revascularization ( TVR ) . Furthermore recurrent myocardial infarction ( MI ) stroke within first 30 day record . Bleeding complication record hospital stay . Minor bleed complication define bleeding vascular access site , require blood transfusion , leading premature ( &lt; 12 hour ) cessation abciximab IV infusion . Major bleed complication define bleeding require cessation abciximab infusion subsequent blood transfusion and/or vascular surgery . After 30 day patient contact telephone , subsidiary letter . All possible event within period confirm check hospital source data . All end-points evaluate independent committee unaware study-group assignment . No patient lose follow . All patient give write informed consent . The study approve local ethic committee Danish Medicines Agency carry concordance Helsinki-II Declaration GCP requirement .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Usually inclusion criterion Abciximab , : Adjunct PCI prevention cardiac ischemic complication : In patient undergo PCI In patient UA respond conventional medical therapy PCI plan within 24 hour Usually exclusion criterion Abciximab , : Active internal bleeding , recent ( within 6 week ) gastrointestinal ( GI ) genitourinary ( GU ) bleed clinical significance History cerebrovascular accident ( CVA ) within 2 year , CVA significant residual neurological deficit Bleeding diathesis Administration oral anticoagulant within 7 day unless prothrombin time le equal 1.2 time control , thrombocytopenia ( &lt; 100,000 cells/µL ) Recent ( within 6 week ) major surgery trauma Intracranial neoplasm Arteriovenous malformation , aneurysm Severe uncontrolled hypertension Presumed document history vasculitis Use intravenous dextran percutaneous coronary intervention , intent use intervention Known hypersensitivity component product murine protein .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Abciximab</keyword>
	<keyword>Reo-Pro</keyword>
	<keyword>Intracoronary</keyword>
	<keyword>PCI</keyword>
</DOC>